and efficiency that are required to support earlier stage studies
DALLAS (PRWEB) September 22, 2008
"Over the next five years, the major growth in EDC adoption will result from improvements in "clock-speed" and efficiency that are required to support earlier stage studies," said Connor. "PDS has consistently proven its ability to deliver the benefits of EDC to the entire marketplace, not only those late stage studies with very large budgets. No other supplier matches PDS' record in this area."
PDS' eClinical technology suite is the foundation that enables PDS to deliver high-quality clinical data services quickly and efficiently. As the director of product development, Connor will help define PDS' product strategy and services architecture.
"Chris has demonstrated an ability to identify technology and market trends well before they become apparent," said Mark Weinstein, CEO of Bio-Imaging Technologies. "It's this eye toward the future that establishes him as an industry thought leader. To state it simply, Chris just gets it. We're excited to have Chris join our team, and I expect PDS to accelerate its success as a premier provider of clinical data services."
Prior to joining Bio-Imaging Technologies, Connor was senior research analyst at Health Industry Insights, an IDC company. At Health Industry Insights, Connor managed the Clinical Development Strategy and Technology service where he provided research and market analysis on key topics in the life sciences area. Leveraging his experience in clinical development and IT, Connor focused on assessing the effect of eClinical software and solutions with the potential to deliver value in the late stage drug development and clinical trial areas. Connor's expertise included adaptive clinical trial design, EDC, clinical trial management systems (CTMS) technologies, electronic patient reported outcomes (ePRO), digital imaging and identifying emerging technologies and market trends in the life science industry.
In previous positions, Connor held responsibility for business operations at WorldCare Clinical, an early leader in the imaging core lab market. Before that, Connor was a principal in a consulting firm dedicated to best practices in new product innovation and development. Connor has also led product management and technical marketing efforts at Lucent Technologies, Brix Networks, 3Com, and Shiva Corporation.
PDS and Connor will be at the Society of Clinical Data Management (SCDM) 14th Annual Conference at the Hyatt Regency Dallas, September 21-24 (booth #106/08). Additional information about Phoenix Data Systems is available at http://www.phoenixdatasystems.net.
Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its Core Labs in Newtown, PA, and Leiden, The Netherlands, along with business offices in the United States, The Netherlands, Germany and France. Phoenix Data Systems, Inc., a subsidiary of Bio-Imaging Technologies, is a leading global clinical data services provider of electronic data capture (EDC) services and a comprehensive array of broadly interoperable eClinical data solutions to the pharmaceutical and biotechnology industries. Phoenix Data Systems delivers full service EDC, a unique combination of electronic data capture, interactive voice response, reporting, and data management solutions. Through its CapMed Personal Health Management Suite, Bio-Imaging provides its Personal HealthKey™ technology, the Personal Health Record (PHR) software, and CapMed Patient Portal allowing patients to better monitor and manage their health care information. Additional information about Bio-Imaging is available at http://www.bioimaging.com.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.